SYBX vs MIRM vs ARWR vs RCKT vs BEAM

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -100. 0% for Synlogic, Inc. (SYBX). Analysts rate Mirum Pharmaceuticals, Inc. (MIRM) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mirum Pharmaceuticals, Inc.

(MIRM) delivered a total return of +504. 7%, compared to -98. 7% for Synlogic, Inc. (SYBX). Over 10 years, the gap is even starker: ARWR returned +1162% versus SYBX's -98. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mirum Pharmaceuticals, Inc.

(MIRM) is the lower-risk stock at 0. 98β versus Beam Therapeutics Inc. 's 2. 08β — meaning BEAM is approximately 112% more volatile than MIRM relative to the S&P 500. On balance sheet safety, Rocket Pharmaceuticals, Inc. (RCKT) carries a lower debt/equity ratio of 9% versus 102% for Mirum Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -100. 0% for Synlogic, Inc. (SYBX). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to 26. 4% for Rocket Pharmaceuticals, Inc.. Over a 3-year CAGR, MIRM leads at 89. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Synlogic, Inc.

(SYBX) is the more profitable company, earning 0. 0% net margin versus -57. 2% for Beam Therapeutics Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARWR leads at 11. 9% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — ARWR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Mirum Pharmaceuticals, Inc.

(MIRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +711. 2% 10Y return). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MIRM: +711. 2%, BEAM: +72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SYBX is a small-cap quality compounder stock; MIRM is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock; RCKT is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.